https://www.selleckchem.com/pr....oducts/favipiravir-t
LAN publications cover all relevant topics of BT therapy throughout a period of more than 20 years. This constitutes a publication basis resembling those of other BT drugs. None of the LAN publications presents data contradictory to those generated with other BT type-A drugs. LAN seems to have a similar efficacy and safety features when compared to onabotulinumtoxinA using a 11 LAN- onabotulinumtoxinA conversion ratio. Large controlled multicentre studies will become necessary for LAN's registrations in Europe and North Americ
Like
Comment
Share
